High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target.
Alice Dawson, Lindsay B Tulloch, Keri L Barrack, William N Hunter
Index: Acta Crystallogr. D Biol. Crystallogr. 66(Pt 12) , 1334-40, (2010)
Full Text: HTML
Abstract
Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species. These protozoa cause serious diseases for which current therapies are inadequate. High-resolution structures have been determined, using data between 1.6 and 1.1 Å resolution, of T. brucei PTR1 in complex with pemetrexed, trimetrexate, cyromazine and a 2,4-diaminopyrimidine derivative. The structures provide insight into the interactions formed by new molecular entities in the enzyme active site with ligands that represent lead compounds for structure-based inhibitor development and to support early-stage drug discovery.
Related Compounds
Related Articles:
2014-12-19
[J. Chromatogr. A. 1373 , 106-13, (2014)]
2015-02-01
[Acta Trop. 142 , 149-55, (2014)]
2013-06-01
[Food Chem. 138(2-3) , 1610-5, (2013)]
2012-01-13
[J. Chromatogr. A. 1220 , 101-7, (2012)]
2011-12-01
[J. Econ. Entomol. 104(6) , 1771-3, (2011)]